Cancer screening involves early detection coupled with early intervention. For cancer screening to reduce cancer mortality, the cancer must be detected sufficiently early and the early intervention must be effective. For cancer screening to minimize harms, the cancers detected early should, to the extent possible, exclude cancers that would not cause medical problems in a person's lifetime (a phenomenon known as overdiagnosis). Detection of overdiagnosed cancers leads to unnecessary work-ups, biopsies, and treatment. The gold standard for evaluating benefits and harms of cancer screening is a randomized controlled trial (1).
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Recently, with enthusiasm over advances in biomarker and imaging technology, early detection of cancer has taken a more prominent role in cancer research. Although the performance evaluation of early detection tests is only one component in evaluating cancer screening (and good performance of an early detection test does not necessarily translate into a reduction in cancer mortality), it is important for cancer researchers to understand how best to evaluate the performance of early detection tests. Researchers need good methods for identifying those early detection tests that are most promising for further investigation in a randomized trial in which the early detection test triggers early intervention (2, 3) . Researchers also need good methods for identifying factors or making comparisons that could improve the performance of existing early detection tests (4) . An important and useful technique for evaluating the performance of diagnostic medical tests is the receiver operating characteristic (ROC) curve (5) . However, for evaluating early detection tests of cancer, ROC curves have been either underused or not always used in the best manner. This commentary explains why ROC curves should be the primary method for evaluating the performance of early detection tests of cancer. It also discusses special considerations in applying ROC curves in particular applications.
OVERVIEW OF ROC CURVES FOR EVALUATING TESTS FOR THE EARLY DETECTION OF CANCER
Early detection of cancer fundamentally involves a rule for classifying asymptomatic subjects as likely having cancer (ideally excluding overdiagnosed cancers) or not. There are two principal types of errors involved in tests for the early detection of cancer: classifying cancers as non-cancers and classifying non-cancers as cancers. Consequently, measures of performance should have two components related to the two types of errors. Single measures of performance, such as the odds ratio (in a 2 × 2 table with margins of cancer/no cancer and classifications of positive/negative), do not fully characterize performance and are therefore not appropriate.
By convention, the performance of a classification rule is usually summarized by the following two quantities related to the two types of errors: true-positive rate and false-positive rate. In this context, the true-positive rate is the probability that a subject with cancer is correctly classified as having cancer, and the false-positive rate is the probability that a subject without cancer is incorrectly classified as having cancer. (The truepositive rate is also called sensitivity and one minus the falsepositive rate is also called specificity.) For an ideal classification rule, the true-positive rate is one and the false-positive rate is zero. For cancer screening, where the target cancer typically has a very low prevalence in the screened population, the falsepositive rate needs to be very low; otherwise, an inordinate number of screened healthy subjects will have unnecessary diagnostic work-ups or biopsies. The magnitudes of acceptable false-positive rates and true-positive rates depend on the corresponding costs and perceived benefits. For mammography screening with a positive result stringently defined as a recommendation for biopsy, the false-positive rate was 0.01 and the true-positive rate was 0.80 (6, 7) . [Some investigators define the false-positive rate on the basis of the decision to work-up any suspicious abnormality, yielding a false-positive rate of 0.065 for mammography (8) .] These target values of the false-positive rate and true-positive rate can serve as a benchmark for other cancer screening evaluations (2, 6) . With cancer screening, a low false-positive rate is necessary for a reasonable positive predictive value, which is the probability of cancer given a positive screen. For example, with a false-positive rate of 0.01, a truepositive rate of 0.80, and a cancer prevalence of 0.001, the positive predictive value would be 0.074. However, for a falsepositive rate of 0.05, a true-positive rate of 0.80, and a cancer prevalence of 0.001, the positive predictive value is only 0.016. To put the target values of the false-positive rate and the truepositive rate into perspective, an odds ratio corresponding to a false-positive rate of 0.01 and a true-positive rate of 0.80 would equal 396 (2), which is much higher than in most epidemiologic studies of cancer risk factors.
The ROC curve is a graphical display of the false-positive rate and the true-positive rate from multiple classification rules. Typically, the true-positive rate is on the vertical axis and the false-positive rate is on the horizontal axis. Each classification rule generates a point on the graph. The traditional ROC curve arises when a continuous value is measured in each subject and the classification is positive if the value is above a threshold. As the threshold varies, a new classification rule is created, and the resulting plot is a single curve.
More generally, the graph displays a cloud of (false-positive rate, true-positive rate) points, and the optimal ROC curve is the line connecting the points highest and farthest to the left (6) (Fig. 1) . The rationale for the optimal ROC curve is that a) one wants the highest true-positive rate for a given false-positive rate, and b) one can specify a rule on the ROC line linking two (false-positive rate, true-positive rate) points by applying the rule for one point with some probability and the rule for the other point with one minus that probability. However, in practice one would like one of the points on the optimal ROC curve to lie near the target false-and true-positive rates.
For the reasons given above, interest is in the part of the ROC curve corresponding to a low false-positive rate when evaluating an early detection test of cancer in asymptomatic people. This is particularly true when the follow-up test for a positive result is invasive or is associated with a risk.
ROC CURVES FOR BIOMARKERS
The development of gene expression microarrays and highthroughput mass spectrometry for proteomics research has spurred the search for new biomarkers for the early detection of cancer. In preliminary biomarker studies (9) (10) (11) , gene expression arrays and proteomic methods are used to identify markers that discriminate between symptomatic cancers and non-cancers. In subsequent biomarker studies (6), proteins (or possibly protein patterns) in stored serum are used to identify markers that discriminate between asymptomatic cancers and non-cancers. In both types of studies, ROC curves are needed to find the classification rules closest to the target false-and true-positive rates.
There are two important considerations in creating ROC curves for early detection biomarkers, regardless of the technology. First, because the number of potential classification rules is extremely large, a major concern in the analyses is overfitting, which means that if one investigates enough classification rules then, by chance, one of them is likely to perform well. The following simple approach for generating ROC curves for biomarkers mitigates the effect of overfitting. Using a common statistical practice, the data are randomly split into training and test samples. This approach works best if one can propose a relatively small number (perhaps at most 30) of classification rules for consideration in the training sample. To create the classification rules, there may be some preliminary selection of markers on the basis of looking at the performance of each marker separately. As described below, some of the rules also can be generated by "and" or "or" combinations of simpler rules. Of course, more complicated rules can also be investigated, and trying to identify the best classification rules is a major area of statistical research.
An optimal ROC curve is created based on the training sample, and one would select the few rules closest to the target false-positive rate and true-positive rate. [Because positive predictive value is more dependent on the false-positive rate than on the true-positive rate (6), the target false-positive rate is the key quantity for selecting the rules.] These few selected rules are evaluated in the test sample to obtain a definitive ROC curve in the region of interest. If the training sample involved only very few rules specified before data analysis, a test sample might not be needed. By contrast, if the test sample were used to winnow down a much larger number of possible rules, another test sample or, better yet, a validation sample from another sample should be used to obtain a definitive ROC curve (2, 6) . Although cross-validation methods are also used to avoid overfitting (12), it is not clear how to apply them to this framework involving ROC curves.
A second important consideration in creating ROC curves for early detection biomarkers is the spectrum of cancer in preliminary studies. A straightforward analysis compares specimens from subjects with and without symptomatic cancer (2) . However, one might also compare specimens from cancer at a particular stage with non-cancers. Although the resulting "ROC curve" is not a true ROC curve (because it ignores the possible classification into other cancer stages), it is informative when keeping in mind that different true-positive rates are expected than if all the cancers were compared with non-cancers. To obtain appropriate estimates of false-positive rates, it is also important that the spectrum of control conditions in the study reflect the control conditions in the general population (2) .
This discussion is limited to biomarkers that are used directly for early detection, where a low false-positive rate is required. One might also be interested in either biomarkers for possible cancer precursors (e.g., adenomas) or those that would be used in conjunction with a more invasive test (e.g., sigmoidoscopy). In these other situations, one would often be interested in a different part of the ROC curve (e.g., higher false-and truepositive rates) than discussed here.
ROC Curves for Gene Expression Microarrays
A gene expression microarray experiment for early detection might compare tissue specimens from subjects with and without cancer, where the outcome per gene per subject is the logarithm of the ratio of intensities of two dyes on a microarray locus. If the sample size is small, as is often the case, the analysis is generally limited to ranking genes by differential expression (9, 13) . For ranking genes for early detection, Pepe (13) proposed computing the partial area under the ROC curve (pAUC) near a low false-positive rate of interest. Results from gene expression arrays cannot be used directly for screening purposes, because obtaining tissue samples from the targeted organ would be too invasive. It may be possible instead, on the basis of the rankings of differential expression, knowledge of the role of the gene, and the availability of an antibody assay for the protein specified by the gene, to identify a protein for further study as a noninvasive early detection test (9) .
With the development of high-throughput antibody assays for multiple proteins, it should become easier to translate gene expression information from tissue samples to a noninvasive test for proteins, even when many genes are involved. This development will likely spur the search for screening classification rules based on multiple genes rather than a single gene. With a sufficiently large sample size, ROC curves could play an important role in identifying the most promising classification rules based on multiple genes.
There are many techniques for creating classification rules that could be applied to the classification of multiple genes for the early detection of cancer. In light of results showing that simpler classification methods perform best in some microarray studies classifying tumor types (14) and to illustrate how different rules give rise to an ROC curve, I suggest the following simple approach for classifying multiple genes for early detection. To minimize overfitting the data, the general paradigm of using a training sample to formulate the classification rules and a test sample for creating the definitive ROC curve can be followed. In the training sample, the highest ranking genes based on the pAUC could be selected, and those pAUCs could be combined to generate a score. Extending the compound covariate approach (15) to early detection, one possible score is the sum, over the selected genes, of pAUCs raised to a power. With a high power, the score essentially combines genes via an "or" rule (because positive classification will arise if any gene has a high pAUC). Another possible score is the product, over selected genes, of pAUCs. This score more closely approximates an "and" rule for combining genes because if pAUC is small for any gene, then the score will be small. Compared with a rule based on a single gene, rules based on an "or" combination increase both the true-positive and false-positive rates, whereas rules based on an "and" combination decrease both the truepositive and false-positive rates.
Various classification rules can be created by varying the threshold for calling a score positive or varying the power in the "or" rule. Furthermore, to create more diversity in the classification rules, instead of selecting only the highest ranking genes in the training sample (which might be highly correlated), it is possible to select some genes with slightly lower rankings that have expression profiles less correlated with other expression profiles. The classification rules could be used to generate many points (each corresponding to a false-and true-positive rate) in the test sample, from which an optimal ROC curve can be identified.
The ROC curve in the test sample should provide useful information about genes related to carcinogenesis. Genes with highly differential expressions that are on the "causal pathway" of the carcinogenesis process should have low false-positive rates and high true-positive rates. Highly differential genes that serve "housekeeping" functions or have expression patterns that represent epiphenomenona are likely to have higher falsepositive rates. However, for early detection tests, false-positive and true-positive rate values based on gene expression provide only preliminary information. After the proteins specified by the genes are identified, it is necessary to derive new classification rules and a more definitive ROC curve (as described in the section on stored samples) based on an early detection test involving the corresponding protein antibodies.
ROC Curves for Proteomic Patterns
A proteomic experiment for early detection might compare specimens from some subjects with cancer and some without cancer, with the outcome being a list of mass/charge ratios (rounded to a specified tolerance) where substantial mass spectrometry peaks occur. Although a mass/charge ratio does not necessarily correspond to a specific protein, it still can be useful for classification purposes.
ROC curves can play an important role in identifying promising markers and reporting results. Following the general paradigm, in the analysis of proteomic outcomes, one should randomly assign the subjects into training and test samples, as in Petricoin et al. (10, 11) . Then, multiple classification rules should be investigated using an ROC curve to determine whether any have the low false-positive rates and high true-positive rates needed for early detection.
Investigating proteomic markers for ovarian cancer, Petricoin et al. (10) reported that one rule gave a false-positive rate of 0.05 and a true-positive rate of 1.00 in the test sample. However, ovarian cancer screening applications require a lower falsepositive rate (16) (17) (18) because the work-up of a positive test involves major surgery, such as an exploratory laparotomy. Investigating proteomic markers for prostate cancer, Petricoin et al. (11) reported that one rule had a false-positive rate of 0.22 and a true-positive rate of 0.95 in the test sample. This falsepositive rate is too high for screening by the marker alone, but if the marker were used with another screening measure such as that for the prostate specific antigen, it might have an acceptable false-positive rate and a true-positive rate.
Investigating and reporting multiple rules should be done to create an optimal ROC curve in the test sample that might indicate a rule with an acceptable false-positive rate and truepositive rate. For example, by listing the mass/charge ratios in the training sample that appear only in subjects with cancer and those that appear only in subjects without cancer, it is possible to create various classification rules, such as classifying a subject in the test sample as positive if he has all (or most) of the mass/charge ratios shared by training sample subjects with cancer and only a few of the mass/charge ratios shared by training sample subjects without cancer. Changing either the tolerance at which the mass/charge ratios are rounded or the definition of a substantial peak would yield additional rules. More complicated rules can also be created. Each rule generates a false-positive rate and true-positive rate in the test sample, which can be used to create an optimal ROC curve. and continue to play, an important role, but some special considerations are involved.
Typically, analysis of asymptomatic cancers is based on stored samples from a prospective study in which some subjects were later diagnosed with the cancer of interest. These later diagnosed cancers should be restricted only to analyses of clinically diagnosed cancers. Otherwise, with screen-detected cancers, there is a strong possibility that some of the cancers would be overdiagnosed, limiting their relevance to early detection. Samples from non-cancer subjects who are not representative of the general population should not be used, because such subjects might have conditions that could artifactually increase the falsepositive rate (2) .
In analyzing the data to determine how various proteins (or proteomic patterns) in stored serum predict asymptomatic cancer versus no cancer, the same principle of training and testing samples applies. There are also special analytical opportunities involving the longitudinal collection of stored samples for each subject. Because changes over time may be predictive of cancer, they should be included in the classification rule. For example, if each subject has two measurements of prostate specific antigen at roughly the same interval, one could include the slope as a potential marker (6) . With multiple measurements of ordered categories at regular intervals, it is possible to specify rules that incorporate changes over time, such as at least one marker in the second highest or highest category over a certain period of time, with evaluation using reverse-time Markov chains (19) .
ROC CURVES FOR SUBJECTIVE RATINGS
Some types of cancer screening, such as mammography, require subjective categorical ratings of the likelihood of a malignant cancer. A typical rating scale involves five categories: normal, probably benign, indeterminate, suspicious, and highly suspicious. For evaluating the performance of these early detection tests, dividing the highly suspicious category into subcategories is helpful because it yields more data near the low falsepositive rates of interest. Early detection studies with subjective ratings include investigating factors that can improve detection performance as well as studies comparing different imaging modalities. ROC curves have an important role in the data analysis, but special considerations apply.
In a comparison of the performance of two groups of raters, each rater ultimately makes a yes or no decision, a recommendation or no recommendation for biopsy (or further work-up). For each group of raters, one could simply compute the falsepositive rate and the true-positive rate associated with the decision. However, unless one group of raters has both a statistically significantly higher true-positive rate and a statistically significantly lower false-positive rate than the other group, this comparison is not very informative, because both groups of raters could simply be making decisions according to the same ROC curve but with a different threshold for calling a result positive. By comparing ROC curves for each group of raters, differences in decision-making thresholds between the raters do not muddle the conclusions.
An important issue is how best to compare ROC curves. With data from diagnostic testing (i.e., testing that rules in or out clinically suspected conditions in a symptomatic patient), comparisons are sometimes based on the entire area under the ROC curve (AUC). Hanley and McNeil (20) interpreted the AUC as "the probability...that in randomly paired normal [non-diseased] and abnormal [diseased] images, the perceived abnormality of the two images will allow them to be correctly identified." They also showed that the AUC could be estimated using a Wilcoxon statistic, a nonparametric statistic for comparing entire distributions. However, these considerations are not applicable to early detection, where random pairing is not a useful construct and, as detailed earlier, only a small part of the distribution (corresponding to a low false-positive rate) is of interest. Focus should be on the part of the ROC curve with clinical relevance (5) (6) (7) 21, 22) .
It is sometimes argued that, although the mean false-positive rate is low for mammography, some radiologists are making recommendations for further work-up at a level where the falsepositive rate is high. Support for this view comes from a study (23) of false-and true-positive rates in which 108 radiologists examined mammograms from 45 women with cancer, 15 women with benign breast disease, and 19 women without cancer. However, this study may not reflect the false-positive rate in practice because the highly "enriched" sample of cancers may have affected the threshold for recommending further work-up. Moreover, even if a few radiologists are making decisions at a high false-positive rate, it does not imply that the AUC should be used. Using the AUC for evaluation implicitly assumes that the false-positive rates are uniformly distributed from 0 to 1. However, the most weight should be given to the part of ROC curve near the low false-positive rates at which most radiologists make decisions, and the least weight should be given to high falsepositive rates where relatively few radiologists make decisions. The pAUC or true-positive rate at a specified low false-positive rate would approximate this situation.
For this reason, and because a low false-positive rate is needed to avoid a large number of unnecessary work-ups or biopsies, the relevant outcomes for evaluating early detection tests for cancer based on subjective ratings are pAUC or truepositive rate at a specified low false-positive rate. These quantities can be computed by interpolation of points near the target low false-positive rate (7) or by fitting a smooth curve to points on the entire ROC curve. However, in the latter case, care must be taken that points corresponding to irrelevant high falsepositive rates do not dominate the fit.
Identifying Variables That Affect Performance
With subjective ratings, investigators are often interested in identifying variables that affect performance. If the variable describes the rater, such as the amount of training or experience, then that information may be useful for improving performance. In a typical study, each rater is asked to score a set of images, some from subjects with cancer and some from subjects without cancer. For each rater or group of raters, the data consist of pAUC (or true-positive rate at a specified false-positive rate) and levels of risk factors. A regression model or analysis of variance is then fitted (4) . If the variable describes a subject characteristic, such as age, that information might be useful for targeting particular populations for early detection. As an example of the type of calculation, for each rater, a separate pAUC for young and old subjects is computed, and the difference (to take advantage of pairing within rater) is averaged over raters. A current area of statistical research involves more general regression modeling for pAUC.
Comparing Screening Modalities
ROC curves are also useful for comparing screening modalities (7, 22 ) in a manner not confounded by different thresholds in the different modalities. In a typical design, each subject receives both modalities, and raters of one modality are blinded to the results of raters of the other modality (7) . Following the basic principles outlined above, the comparison should be based on pAUC or true-positive rate at a given low false-positive rate rather than AUC. In the last decade, new methodology has been developed called multiple-reader multiple-case (MRMC) ROC analysis, which accounts for correlations among different images from the same subject and images read by the same rater (24) .
A special complication in comparing screening modalities is that cancer status is not known for subjects on whom biopsies are not performed. Consequently, these subjects are either imputed by counting cancers arising after a negative screen as missed on screening, or this complication is circumvented by taking ratios of pAUCs (7) .
One important caveat in interpreting ROC comparisons is overdiagnosis. A higher pAUC may not indicate superior performance if the modality involves a higher fraction of overdiagnosed cancers. To rigorously investigate overdiagnosis, a randomized trial with follow-up after screening would be required.
CONCLUSION
With the appropriate use of ROC curves, investigators of early cancer detection tests can improve their research and presentation of results. With early detection biomarkers, ROC curves help identify the most appropriate classification rules. With subjective ratings, ROC curves avoid confounding resulting from varying thresholds. In both cases, ROC curves help investigators focus on classification rules with low false-positive rates, which are most important for early detection of cancer. However, these ROC curve results should always be put in perspective, because a good classification rule for early detection of cancer does not guarantee that cancer screening will reduce cancer mortality or have a favorable benefit-to-harm ratio. Such information is most efficiently and reliably derived from a randomized controlled trial.
